Monday, 25 Sep 2017

You are here

Jak Inhibition May Ameliorate Pruritus

Last week we reported the results of a metanalysis published in the Journal of Investigative Dermatology showing that certain agents are more effective in managing the pruritus of psoriasis, including the inhibitors of IL-17, Janus kinase (Jak), adalimumab and apremilast. (

Further credence to the effects of Jak inhibition are found in a report from Cell, where researchers from the Dermatology division at the Washington University School of Medicine have examined the role of type 2 cytokines in the activation of sensory neurons that may be involved in pruritus.  

They note that clinical studies demonstrate that JAK inhibitors relieve chronic itching. The current report details five patients with chronic idiopathic pruritus who improved when given tofacitinib. Earlier treatment with other anti-inflammatory drugs failed to help their chronic itching, but within one month of taking tofacitinib, all five patients reported marked relief from severe itching.

These researchers showed that sensory neurons in mice and humans are activated by the type 2 cytokine, interleukin-4 (IL-4). They also showed IL-4 enhances neuronal responsiveness to multiple pruritogens and that sensory neuron-specific deletion of IL-4Rα or JAK1 reduces chronic itch.

The authors believe, "This study reveals an evolutionarily conserved paradigm in which the sensory nervous system employs classical immune signaling pathways to influence mammalian behavior."

Figure thumbnail fx1

The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Rituximab Efficacy in IgG4 Related Disease

PLOS reports  greater than 90% efficacy when rituximab (RTX) is used to treat patients with IgG4-related disease (IgG4-RD). 

Biologic Use in Adult-Onset Still's Disease

 Adult-onset Still's disease (AOSD) is the adult continum of systemic-onset juvenile idiopathic arthritis (SoJIA). Treatment of this febrile polyarticular systemic disorder can be complex, but has been relieved by several specific biologic therapies.

New Recommendations on Biosimilar Use

The introduction of a growing number of biosimilars into the market poses a substantial change in cost of care for patients with inflammatory rheumatologic disorders.  

Turnabout for Baricitinib

Eli Lilly and Company and Incyte Corporation announced today that, after discussions with the U.S. Food and Drug Administration in late August 2017, Lilly will resubmit a revised New Drug Application for baricitinib before the end of January 2018. The resubmission package will include new safety and efficacy data. 

Canakinumab Reduces CV Outcomes in High Risk Patients

The results of a randomized, double-blind trial have shown that canakinumab (CAN), an interleukin-1β inhibitor, given as 150 mg every 3 months, resulted in a significantly lower rate of recurrent cardiovascular events (in high-risk CV patients), independent of lipid-level lowering. The results of the CANTOS studywere simultaneously published in NEJM, Lancet and were presented at the European Society of Cardiology meeting in Barcelona.